The Relationship of Onglyza (Saxagliptin) and Fracture Risk in Type 2 Diabetes

Authors conclude that treatment with Onglyza for type 2 diabetes in older patients was not related with an increased risk of fractures as this was shown by a study encompassing a large population sample. However, an interesting finding between the duration of diabetes and increased risk of bone fracture was discovered, which requires further studies to determine contributing factors.

Read more

Posted in Type II Drugs Medical Research